Anti-tumor necrosis factor therapies reduce serum macrophage inflammatory protein-1alpha in ankylosing spondylitis.
Akbulut
Handan
H
Koca
Suleyman S
SS
Ozgen
Metin
M
Isik
Ahmet
A
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D018501:Antirheumatic Agents / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000097:blood / Q000276:immunology / Q000628:therapy; D054405:Chemokine CCL3 / Q000097:blood* / Q000276:immunology; D006801:Humans; D012720:Severity of Illness Index; D013167:Spondylitis, Ankylosing / Q000097:blood* / Q000276:immunology / Q000628:therapy*; D018709:Statistics, Nonparametric; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors* / Q000276:immunology
D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D054405:Chemokine CCL3; D014409:Tumor Necrosis Factor-alpha